CN114507643A - Pluripotent stem cell derivative for expressing IL-2 and application thereof - Google Patents

Abstract

The invention discloses a pluripotent stem cell derivative expressing IL-2 and an application thereof. The genome of the pluripotent stem cell or the derivative thereof is introduced with a sequence expressing IL-2. The IL-2-expressing pluripotent stem cells or their derivatives of the present invention can be used for autologous cells to induce iPSCs or differentiate into low-immunogenic cells such as MSCs, and they can continuously express IL-2 in vivo for the treatment of IL-2 2Highly expressed tumors and related diseases.

Description

A pluripotent stem cell derivative expressing IL-2 and its application

technical field

The invention belongs to the technical field of genetic engineering, and in particular relates to a pluripotent stem cell expressing IL-2 or a derivative thereof, and related applications.

Background technique

Interleukin-2 (IL-2) is a cytokine in the chemokine family. It is a cytokine derived from multicellular sources (mainly produced by activated T cells) and has pleiotropic effects (mainly promoting the growth, proliferation and differentiation of lymphocytes); it plays an important role in the body's immune response and anti-viral infection. Stimulates the proliferation of T cells that have been initiated by specific antigens or mitogenic factors; can activate T cells and promote the production of cytokines; stimulate the proliferation of NK cells, enhance the killing activity of NK and produce cytokines, induce the production of LAK cells; promote the proliferation of B cells and secretion of antibodies; activation of macrophages. Due to the low production capacity of IL-2 in cancer patients, injection of IL-2 can activate immune cells in the body to produce anti-cancer effects. And different ways of giving IL-2 have different anti-cancer effects. So far, clinical applications have shown that for patients with intermediate and advanced malignant tumors who have been ineffective after conventional surgery, chemotherapy, or radiotherapy, or who still lack effective therapy, IL-2 and LAK can be used to treat patients with certain objective curative effects.

Stem cells are a type of "seed" cells that have the ability to self-renew and differentiate into specific functional somatic cells. They have the potential to regenerate into various tissues and organs and the human body. core and irreplaceable role. According to the degree of stem cell characteristics, stem cells are mainly divided into: totipotent stem cells (Totipotent stem cells), pluripotent stem cells (PSCs) and adult stem cells (adult stem cells). Among them, pluripotent stem cells (PSCs) have almost unlimited self-renewal ability and the potential to develop and differentiate into organs, tissues and cells of all germ layers in the embryo under normal developmental conditions. Typical PSCs mainly include embryonic stem cells (ESCs). ), embryonic germ cells (EGCs), embryonic carcinoma cells (ECCs), and induced pluripotentstem cells (iPSCs). It can pass ethical restrictions to a certain extent, so it has a very far-reaching and wide-ranging application prospect.

At present, in the field of cell therapy, the issue of allogeneic immune compatibility is still a major problem. In recent years, there have been many reports that by knocking out B2M, CIITA and other genes, the expression of HLA-I and HLA-II cells surface or their own genes is lost, so that cells have immune tolerance or escape T/B cell-specific immune responses, resulting in The immune-compatible universal PSCs have laid an important foundation for the wider application of universal PSC-derived cells, tissues and organs. It has also been reported that cells overexpress CTLA4-Ig and PD-L1 to inhibit allogeneic immune rejection. Recently, it has been reported that while knocking out B2M and CIITA, CD47 is knocked in, so that the cells can escape from the specific immune response, but also have immune tolerance or escape the innate immune response of NK cells, so that the cells have More comprehensive and stronger immune compatibility features. However, these regimens are either not fully immune compatible, and allogeneic immune rejection still occurs through other means; or they completely eliminate the allogeneic immune rejection response, but the cells of the donor-derived graft lose their antigen-presenting ability at the same time. capacity, which poses a great risk to the receptor for diseases such as tumorigenicity and viral infection.

For this reason, some studies have also reported that, instead of directly knocking out B2M, while knocking out HLA-A, HLA-B or CIITA together, HLA-C was retained, and 12 HLA-C were constructed that covered more than 90% of the population. C immunomatching antigen, so that the transplanted cells still have a certain degree of antigen presentation function, and at the same time can inhibit the innate immune response of NK cells through HLA-C. However, these cells, firstly, the types of antigens presented by HLA-I antigens have been reduced by more than two-thirds, and the integrity of the antigens that can be presented has been greatly and irreversibly reduced. The presentation is highly biased, and still retains a considerable degree of risk of diseases such as tumorigenesis and viral infection, and its pathogenic risk is higher in the case of simultaneous knockout of CIITA; second, 12 high-frequency immunomatching The ethnic differences of HLA-C antigens are very large. Through our verification and calculation, some regions can only account for 70% of the proportion. However, China, India and other populous countries currently do not have authoritative large-scale HLA data display. The use of type PSCs is still subject to the huge matching vacancy test; thirdly, this method will undergo several iterations of gene editing work. Based on at least two rounds of single-cell isolation and culture for each gene editing, the whole process requires at least more than six rounds of single-cell isolation and culture. Cell isolation and culture, these processes are inevitably and highly likely to cause various unpredictable mutations in cells due to multiple off-target gene editing or chromatin instability or due to a large number of single-cell passages and proliferations, and then induce various problems such as carcinogenesis and metabolic diseases . It can be seen that this type of immunocompatibility program is also an expedient measure in the "transition period", and there are still many problems that have not been better resolved.

In addition, some people have designed suicide genes to induce killing after the donor tissue and cells become diseased. The consequences of doing so will cause severe tissue necrosis, cytokine storms and other unpredictable disease risk problems, and such designed cells Another problem is that after killing, there will be no suitable donor cells, tissues and organs.

SUMMARY OF THE INVENTION

In view of the deficiencies in the prior art, the purpose of the present invention is to provide an IL-2-expressing pluripotent stem cell or a derivative thereof.

Another object of the present invention is to provide an immunocompatible pluripotent stem cell or a derivative thereof expressing IL-2. One of the schemes is to knock out the B2M and/or CIITA genes in the genome of pluripotent stem cells or their derivatives; the other scheme is to knock in the expression sequences of immune-compatible molecules in the genomes of pluripotent stem cells or their derivatives.

Another object of the present invention is to provide an immunocompatible and reversible IL-2-expressing pluripotent stem cell or a derivative thereof. The expression of immune-compatible molecules introduced into the genome of pluripotent stem cells or their derivatives is regulated by an inducible gene expression system, and the opening and closing of the inducible gene expression system is regulated by exogenous inducers. When immune-compatible molecules are normally expressed, the expression of genes related to immune response in pluripotent stem cells or their derivatives is inhibited or overexpressed, which can eliminate or reduce the allogeneic immune rejection response between donor cells and recipients. When the donor cell becomes diseased, the expression of immune-compatible molecules can be turned off by inducing an exogenous inducer to restore the antigen-presenting ability of the donor cell, so that the recipient can remove the diseased donor cell.

The technical scheme adopted by the present invention is:

A pluripotent stem cell or a derivative thereof whose genome is introduced with an IL-2 expression sequence.

As preferred:

The knock-in site of the IL-2 expression sequence is the genomic safety site of the pluripotent stem cell or its derivative.

Preferably, the genome security site includes one or more of the AAVS1 security site, the eGSH security site, and the H11 security site.

As another technical solution of the present invention, the B2M and/or CIITA genes of the pluripotent stem cells or derivatives thereof are knocked out, thereby obtaining an immune-compatible pluripotent stem cell or its derivatives expressing IL-2.

As another technical solution of the present invention, one or more immune-compatible molecule expression sequences are also knocked into the genome security site, and the immune-compatible molecules are used to regulate the pluripotent stem cells or their derivatives with allogeneic Expression of immune rejection-related genes, thereby obtaining an immune-compatible pluripotent stem cell or a derivative thereof expressing IL-2.

The genes associated with the immune response include:

(1) Major histocompatibility complex genes, including HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DQA1, HLA - at least one of DQB1, HLA-DPAl and HLA-DPB1;

(2) Major histocompatibility complex-related genes, including at least one of B2M and CIITA.

The immunocompatible molecule includes any one or more of the following:

(1) Immune tolerance-related genes, including CD47 or HLA-G;

(2) HLA-C class molecules, including HLA-C multiple alleles with a proportion of more than 90% in the population, or fusion protein genes composed of more than 90% of HLA-C multiple alleles and B2M;

(3) shRNA and/or shRNA-miR of major histocompatibility complex genes;

(4) shRNA and/or shRNA-miR of major histocompatibility complex-related genes.

As preferred:

The target sequence of the B2M shRNA and/or shRNA-miR is at least one of SEQ ID NO.2 to SEQ ID NO.4;

The target sequence of the shRNA and/or shRNA-miR of the CIITA is at least one of SEQ ID NO.5 to SEQ ID NO.14;

The target sequence of the HLA-A shRNA and/or shRNA-miR is at least one of SEQ ID NO.15-SEQ ID NO.17;

The target sequence of the HLA-B shRNA and/or shRNA-miR is at least one of SEQ ID NO.18-SEQ ID NO.23;

The target sequence of the HLA-C shRNA and/or shRNA-miR is at least one of SEQ ID NO.24-SEQ ID NO.29;

The target sequence of the shRNA and/or shRNA-miR of the HLA-DRA is at least one of SEQ ID NO.30 to SEQ ID NO.39;

The target sequence of the shRNA and/or shRNA-miR of the HLA-DRB1 is at least one of SEQ ID NO.40 to SEQ ID NO.44;

The target sequence of the shRNA and/or shRNA-miR of the HLA-DRB3 is at least one of SEQ ID NO.45-SEQ ID NO.46;

The target sequence of the shRNA and/or shRNA-miR of the HLA-DRB4 is at least one of SEQ ID NO.47-SEQ ID NO.56;

The target sequence of the shRNA and/or shRNA-miR of the HLA-DRB5 is at least one of SEQ ID NO.57-SEQ ID NO.65;

The target sequence of the shRNA and/or shRNA-miR of the HLA-DQA1 is at least one of SEQ ID NO.66-SEQ ID NO.72;

The target sequence of the shRNA and/or shRNA-miR of the HLA-DQB1 is at least one of SEQ ID NO.73-SEQ ID NO.82;

The target sequence of the shRNA and/or shRNA-miR of the HLA-DPA1 is at least one of SEQ ID NO.83-SEQ ID NO.92;

The target sequence of the shRNA and/or shRNA-miR of the HLA-DPB1 is at least one of SEQ ID NO.93-SEQ ID NO.102.

Further preferred: the genome security site also knocks in shRNA and/or miRNA processing complex genes and related genes and/or anti-interferon effector molecules, wherein: shRNA and/or miRNA processing complex genes and related genes include Drosha , at least one of Ago1, Ago2, Dicer1, Exportin-5, TRBP (TARBP2), PACT (PRKRA) and DGCR8; the interferon effector molecule is anti-PKR, 2-5As, IRF-3 or IRF-7 At least one of shRNA and/or shRNA-miR.

Preferably, the target sequences of the anti-PKR, 2-5As, IRF-3 or IRF-7 shRNA and/or shRNA-miR are SEQ ID NO.105-SEQ ID NO.164.

Preferably: the expression framework of the major histocompatibility complex gene, major histocompatibility complex-related gene, anti-PKR, 2-5As, IRF-3 or IRF-7 shRNA and/or shRNA-miR As follows:

(1) shRNA expression framework: from 5' to 3', it includes the shRNA target sequence, the stem-loop sequence, the reverse complement of the shRNA target sequence, and Poly T; the two reverse complement target sequences are separated by a stem-loop sequence in the middle. The hairpin structure is finally connected with Poly T as the transcription terminator of RNA polymerase III.

Preferably, the length of the stem-loop sequence in the shRNA expression framework is 3-9 bases; the length of the poly T is 5-6 bases.

(2) shRNA-miR expression framework: obtained by replacing the target sequence in microRNA-30 or microRNA-155 with the aforementioned shRNA-miR target sequence.

The above-mentioned expression framework can add a constitutive promoter or an inducible promoter at the 5' end as required, such as U6 promoter, H1 promoter, and matching promoter regulatory elements.

As another technical solution of the present invention: an inducible gene expression system is also introduced into the genome of the pluripotent stem cells or their derivatives for regulating the expression of immune-compatible molecules, thereby obtaining an immune-compatible and reversible expression of IL-2 pluripotent stem cells or their derivatives.

The inducible gene expression system includes a Tet-Off system or a dimer inducible expression system.

The above-mentioned pluripotent stem cells include embryonic stem cells, embryonic germ cells, embryonic cancer cells, or induced pluripotent stem cells;

The above-mentioned pluripotent stem cell derivatives include adult stem cells differentiated from pluripotent stem cells, cells or tissues of each germ layer. The adult stem cells include mesenchymal stem cells and neural stem cells.

As another technical solution of the present invention, the nucleotide sequence of the IL-2 is shown in SEQ ID NO.1, and the signal peptide sequence is shown in SEQ ID NO.183.

The application of the above-mentioned pluripotent stem cells or derivatives thereof in the preparation of IL-2 high-expressing tumor therapeutic drugs.

A formulation comprising the above-described pluripotent stem cells or derivatives thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

The beneficial effects of the present invention are:

The IL-2-expressing pluripotent stem cells or derivatives thereof of the present invention can be used for autologous cells to induce iPSCs or differentiate into low-immunogenic cells such as MSCs, and they can continuously express IL-2 in vivo for the treatment of IL-2. 2 It is highly expressed in tumors and related diseases, which is conducive to the development of cancer therapy.

The immune-compatible pluripotent stem cells or derivatives thereof expressing IL-2 of the present invention, because the B2M and CIITA genes in the pluripotent stem cells or their derivatives are knocked out, or the immune-compatible molecule expression sequences are introduced into their genomes, so such The immunogenicity of pluripotent stem cells or their derivatives is low, and when transplanted into the recipient, it can overcome the problem of allogeneic immune rejection between the donor cells and the recipient, and the donor cells can remain in the recipient for a long time IL-2 is continuously expressed.

The immune compatible reversible pluripotent stem cells or derivatives thereof expressing IL-2 of the present invention are introduced into the genome of an inducible gene expression system and an immune compatible molecular expression sequence. The inducible gene expression system is regulated by exogenous inducers. By adjusting the addition amount, duration and type of exogenous inducers, the inducible gene expression system can be turned on and off, thereby controlling the expression of immune-compatible molecular expression sequences. . And immune-compatible molecules can regulate the expression of immune response-related genes in pluripotent stem cells or their derivatives. When immune-compatible molecules are normally expressed, the expression of genes related to immune response in pluripotent stem cells or their derivatives is inhibited or overexpressed, which can eliminate or reduce the allogeneic immune rejection response between donor cells and recipients, The donor cells can continue to express IL-2 in the recipient for a long time. When the donor cell becomes diseased, the expression of immune-compatible molecules can be induced to shut down by exogenous inducers, thereby reversibly re-expressing HLA class I molecules on the surface of the donor cell, restoring the antigen-presenting ability of the donor cell, and making the recipient It can remove diseased cells, thereby improving the clinical safety of such universal pluripotent stem cells or their derivatives, and greatly expanding their value in clinical applications.

Description of drawings

Figure 1, AAVS1 KI Vector (shRNA, constitutive) plasmid map.

Figure 2, AAVS1 KI Vector (shRNA, inducible) plasmid map.

Figure 3, AAVS1 KI Vector (shRNA-miR, constitutive) plasmid map.

Figure 4, AAVS1 KI Vector (shRNA-miR, inducible) plasmid map.

Figure 5, sgRNA clone B2M-1 plasmid map.

Figure 6, sgRNA clone B2M-2 plasmid map.

Figure 7, sgRNA clone CIITA-1 plasmid map.

Figure 8, sgRNA clone CIITA-2 plasmid map.

Figure 9, Cas9 (D10A) plasmid map.

Figure 10, sgRNA Clone AAVS1-1 plasmid map.

Figure 11, sgRNA Clone AAVS1-2 plasmid map.

Detailed ways

In order to understand the technical content of the present invention more clearly, the following embodiments are given for detailed description in conjunction with the accompanying drawings. It should be understood that these examples are only used to illustrate the present invention and not to limit the scope of the present invention. The experimental method of unreceipted specific conditions in the following examples, usually according to normal conditions, such as people such as Sambrook, molecular cloning: the conditions described in the laboratory manual (NewYork:Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer the proposed conditions. Various common chemical reagents used in the examples are all commercially available products.

1 Experimental materials and methods

1.1 IL-2 expression sequence

The nucleotide sequence for expressing IL-2 is shown in SEQ ID NO.1, the front end of SEQ ID NO.1 is added with the signal peptide sequence SEQ ID NO.183, and the end is added with TGA terminator.

1.2 Stem cells or their derivatives

Pluripotent stem cells can be selected from embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and other forms of pluripotent stem cells, such as hPSCs-MSCs, NSCs, EBs cells. in:

iPSCs: Using our third-generation efficient and safe episomal-iPSCs induction system (6F/BM1-4C), pE3.1-OG--KS and pE3.1-L-Myc--hmiR302 cluster were electroporated into the body In cells, RM1 was cultured for 2 days, BioCISO-BM1 containing 2uM Parnate was cultured for 2 days, BioCISO-BM1 containing 2uM Parnate, 0.25mM sodium butyrate, 3uMCHIR99021 and 0.5uM PD03254901 was cultured for 2 days, and the stem cell medium BioCISO was cultured to 17 The iPSCs clones can be picked in about a day, and the picked iPSCs clones are purified, digested, and passaged to obtain stable iPSCs. For the specific construction method, please refer to: Stem Cell Res Ther. 2017Nov 2;8(1):245.

hPSCs-MSCs: iPSCs were cultured in stem cell medium (BioCISO, containing 10uM TGFβ inhibitor SB431542) for 25 days, digested and passaged at 80-90 confluency (2mg/mL Dispase digestion), and passaged 1:3 into Matrigel-coated cells In the culture plate, then ESC-MSC medium (knockout DMEM medium, containing 10% KSR, NEAA, double antibody, glutamine, β-mercaptoethanol, 10ng/mL bFGF and SB-431542) was cultured, and the medium was changed every day , 80-90 confluency for passage (1:3 passage), continuous culture for 20 days. For the specific construction method, please refer to: Proc Natl Acad Sci US A. 2015; 112(2):530-535.

NSCs: iPSCs were cultured in induction medium (knockout DMEM medium, containing 10% KSR, containing TGF-β inhibitor, BMP4 inhibitor) for 14 days, and rosette-shaped neurons were picked into low-adherence culture plates Cultivated in a 1:1 ratio of DMEM/F12 (containing 1% N2, Invitrogen) and Neurobasal medium (containing 2% B27, Invitrogen), and also containing 20ng/ml bFGF and 20ng/ml EGF, for culture , Digestion using Accutase for digestion and passage. For the specific construction method, please refer to: FASEB J. 2014; 28(11): 4642-4656.

EBs cells: iPSCs with a confluency of 95% were digested with BioC-PDE1 for 6 min, and then scraped into a block using a mechanical scraping method, settled down to the cell mass, and the settled cell mass was transferred to a low-adherence culture plate for use BioCISO-EB1 was cultured for 7 days, and the medium was changed every other day. After 7 days, the cells were transferred to Matrigel-coated culture plates to continue adherent culture with BioCISO. After 7 days, embryoid bodies (EBs) with inner, middle and outer germ layers were obtained. For the specific construction method, please refer to: StemCell Res Ther. 2017Nov 2;8(1):245.

The pluripotent stem cell derivatives also include adult stem cells differentiated from pluripotent stem cells, cells of each germ layer, tissues, and organs; and the adult stem cells include mesenchymal stem cells or neural stem cells.

1.3 Genome Safety Sites

In the technical solution of the present invention, the genomic safety site for gene knock-in can be selected from the AAVS1 safety site, the eGSH safety site, or other safety sites:

(1) AAVS1 safety site

The AAVS1 locus (alias "PPP1R2C locus") is located on chromosome 19 of the human genome and is a validated "safe harbor" site that ensures the intended function of the transferred DNA fragment. This site is an open chromosomal structure, which can ensure that the transferred gene can be transcribed normally, and the insertion of exogenous target fragments at this site has no known side effects on cells.

(2) eGSH safety site

The eGSH safety site is located on chromosome 1 of the human genome and is another "safe harbor" site that has been validated by the paper and can ensure the intended function of the transferred DNA fragment.

(3) Other security sites

The H11 safety site (also called Hipp11), located on human chromosome 22, is a site between the two genes Eif4enif1 and Drg1. It was discovered and named by Simon Hippenmeyer in 2010. Since the H11 site is located in two genes Therefore, the risk of affecting the expression of the endogenous gene after the insertion of the exogenous gene is very small. The H11 locus was verified to be a safe transcriptional activation region between genes and a new "safe harbor" site besides the AAVS1 and eGSH loci.

1.4 Inducible gene expression system

In the technical solution of the present invention, the inducible gene expression system can be selected from: tet-Off system or dimer off expression system:

(1) tet-Off system

In the absence of tetracycline, the tTA protein continues to act on the tet promoter, allowing the gene to continue to be expressed. This system is very useful where transgenes need to be maintained in a state of continuous expression. When tetracycline is added, tetracycline can change the structure of the tTA protein so that it cannot bind to the promoter, thereby reducing the level of gene expression it drives. To keep this system "off", tetracycline must be added continuously.

In the present invention, the sequences of the tet-Off system and one or more immune-compatible molecules are knocked into the genome safety site of pluripotent stem cells, and the expression of immune-compatible molecules can be accurately turned on or off by adding tetracycline, thereby reversibly regulating the expression of immune-compatible molecules. Expression of major histocompatibility complex-related genes in competent stem cells or their derivatives.

(2) Dimer shutdown expression system

Dimer-mediated gene expression regulation system: There are many ways to chemically regulate the transcription of target genes, the most common is the use of allosteric regulators that affect the activity of transcription factors. One such approach is to use dimerization inducers or dimers to reconstitute active transcription factors on inactive fusion proteins. The most commonly used system uses the natural product rapamydn or a biologically inactive analog as the dimerized drug. Rapamycin (or analog) homoplasmic protein FKBP12 (the protein that FKBP binds to FK506) and a large serine-threonine protein kinase called FRAP [FRBP-rapamycin-related protein, or mTOR ( Mammalian target of rapamycin)] has high affinity and the function of binding with these two proteins, so these two proteins are brought together as a heterodimer. To regulate target gene transcription, a DNA binding domain is fused to one or more FKBP domains, and a transcriptional repression domain is fused to amino acid 93 of FRAP, called FRB, which is sufficient to bind the FKBP-rapamycin complex. The two fusion proteins dimerized only in the presence of rapamycin. Transcription of genes with sites that bind to the DNA binding region is thus inhibited.

1.5 Selection of immunocompatible molecules

The immune compatible molecule can regulate the expression of allogeneic immune rejection-related genes in pluripotent stem cells or derivatives thereof. The types and sequences of specific immune-compatible molecules are shown in Table 1:

Table 1 Immunocompatible molecules

The target sequences of the above shRNA or shRNA-miR immune-compatible molecules are shown in Table 2:

Table 2 Target sequences of shRNA or shRNA-miR

In the immune-compatible molecular knock-in schemes in Tables 5-6 below, the shRNA or shRNA-miR sequences of each experimental group were the shRNA or shRNA-miR immune-compatible molecules constructed by using the target sequence 1 in Table 2. Those skilled in the art can understand that shRNA or shRNA-miR immune-compatible molecules constructed with other target sequences can also achieve the technical effects of the present invention, which all fall within the protection scope of the claims of the present invention.

1.6 shRNA/miRNA processing complex genes and anti-interferon effector molecules

The primary miRNA (pri-miRNA) in the nucleus is micro-processed by the complex Drosha-DGCR8, and the pri-miRNA is cleaved into the precursor miRNA (pre-miRNA), which will form a hairpin structure. Next, the pre-miRNA is transported out of the nucleus via the Exportin-5-Ran-GTP complex. The RNaseDicer enzyme, which binds to the double-stranded RNA-binding protein TRBP (TARBP2) in the cytoplasm, cleaves pre-miRNAs to their mature lengths, while the miRNAs are still double-stranded. Finally, it is transported into AGO2 to form RISC (RNA-induced silencing complex). One strand of the final miRNA duplex remains in the RISC complex, while the other is excreted and rapidly degraded. As the main binding protein of Drosha, DGCR8 can bind to pri-miRNA through its two double-stranded RNA binding regions at the C-terminus, recruit and guide Drosha to cleave at the correct position of pri-miRNA to produce pre-miRNA, pre-miRNA It is further processed and cleaved by Dicer and TRBP/PACT to form mature miRNA. The deletion or abnormal expression of DGCR8 can affect the splicing activity of Drosha, which in turn affects the activity of miRNAs, leading to the occurrence of diseases. TRBP can recruit Dicer complex miRNAs to form RISC Ago2.

The present invention utilizes the gene knock-in technology to knock-in the shRNA-miR expression sequences for HLA class I molecules and HLA class II molecules that can be inducible to shut down the expression at the safe site of the genome, preferably, the shRNA that can be inducible to shut down the expression and / or miRNA processing machines include Drosha (Accession number: NM_001100412), Ago1 (Accession number: NM_012199), Ago2 (Accession number: NM_001164623), Dicer1 (Accession number: NM_001195573), Exportin-5 (Accession number: NM_020750), TRBP (Accession number: NM_134323), PACT (Accession number: NM_003690) and DGCR8 (Accession number: NM_022720), so that cells do not occupy the processing of other miRNAs and affect cell function.

In addition, in the process of IFN induction, double-stranded RNA-dependent Protein Kinase (PKR), which is a key factor in the entire cell signal transduction pathway, also has 2',5 'Oligoadenylate synthase (2,5-Oligoadenylate Synthetase, 2-5As), these two enzymes are closely related to dsRNA-induced IFN. PKR can inhibit protein synthesis by phosphorylating eukaryotic transcription factors, make cells stagnate in G0/G1 and G2/M phases, and induce apoptosis, while dsRNA can promote 2-5As synthesis, resulting in non-specific RNase, RNaseL. Heterogeneous activation, degrades all mRNA in cells, and causes cell death. The induction specificity of type I interferon is achieved by members of the IRF transcription factor family. In the absence of the expression of IRF-3 and IRF-7 in cells, type I interferon cannot be induced and secreted in many viral infections. In the absence of an IFN response, co-expression of the two proteins is required to restore it.

The present invention utilizes gene knock-in technology to knock-in the expression sequence of immune compatible molecule shRNA-miR at the safe site of the genome, preferably simultaneously knock-in inducible shut-down expression for inhibiting PKR, 2-5As, IRF-3 and IRF-7 Gene shRNA and/or shRNA-miR expression sequences that reduce dsRNA-induced interferon responses, thereby avoiding cytotoxicity.

There is no restriction on the insertion positions of shRNA/miRNA processing complex-related genes, anti-interferon effector molecules, and immune-compatible molecules at safe sites in the genome, and they can be arranged in any order without interfering with each other or affecting other genes in the genome. structure and function.

The target sequences of specific anti-interferon effector molecules are shown in Table 3.

Table 3 Target sequences of anti-interferon effector molecules

In the anti-interferon effector molecule knock-in scheme in Tables 5 to 6 below, the shRNA or shRNA-miR sequences of each experimental group were shRNA or shRNA-miR immunocompatible molecules constructed by using target sequence 1 in Table 3. Those skilled in the art can understand that shRNA or shRNA-miR immune-compatible molecules constructed with other target sequences can also achieve the technical effects of the present invention, which all fall within the protection scope of the claims of the present invention.

1.7 General framework for immune-compatible molecules, anti-interferon effector shRNAs or shRNA-miRs

The general framework sequences of immunocompatible molecules, anti-interferon effector shRNAs or shRNA-miRs are shown below:

(1) The shRNA constitutive expression framework is:

GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGCTAGCGCCACC(SEQ ID NO.163)N ₁ ...N ₂₁ TTCAAGAGA(SEQ IDNO.164)N ₂₂ ...N ₄₂ TTTTTT

in:

_a . N1... _N21 is the shRNA target sequence of the corresponding gene, and _N22 ... _N42 is the reverse complementary sequence of the shRNA target sequence of the corresponding gene;

b. If the plasmid needs to express shRNA of multiple genes, each gene corresponds to a shRNA expression frame, and then they are seamlessly connected;

c. Constitutive shRNA plasmids with different resistance genes, only the resistance genes are different, and other sequences are the same;

d, N represent A, T, G, C bases;

e, SEQ ID NO.163 is the U6 promoter sequence;

f. SEQ ID NO. 164 is the stem-loop sequence.

(2) The shRNA-inducible expression framework is:

(SEQ ID NO. 165) N ₁ ... N ₂₁ TTCAAGAGA (SEQ ID NO. 166) N ₂₂ ... N ₄₂ TTTTTT

in:

_a . N1... _N21 is the shRNA target sequence of the corresponding gene, and _N22 ... _N42 is the reverse complementary sequence of the shRNA target sequence of the corresponding gene;

b. If the plasmid needs to express shRNA of multiple genes, each gene corresponds to a shRNA expression frame, and then they are seamlessly connected;

c. Constitutive shRNA plasmids with different resistance genes, only the resistance genes are different, and other sequences are the same;

d, N represent A, T, G, C bases;

(3) The shRNA-miR constitutive or inducible expression framework is:

GAGGCTTCAGTACTTTACAGAATCGTTGCCTGCACATCTTGGAAACACTTGCTGGGATTACTTCTTCAGGTTAACCCAACAGAAGGCTAAAGAAGGTATATTGCTGTTGACAGTGAGCG(SEQ ID NO.167)M ₁ N ₁ ...N ₂₁ TAGTGAAGCCACAGATGTA(SEQ ID NO.168)N ₂₂ ...N ₄₂ M ₂ TGCCTACTGCCTCGGACTTCAAGGGGCTACTTTAGGAGCAATTATCTTGTTTACTAAAACTGAATACCTTGCTATCTCTTTGATACATTTTTACAAAGCTGAATTAAAATGGTATAAAT(SEQ ID NO.169)

in:

_a . N1... _N21 is the shRNA-miR target sequence of the corresponding gene, and _N22 ... _N42 is the reverse complementary sequence of the shRNA-miR target sequence of the corresponding gene;

b. If the plasmid needs to express shRNA-miR of multiple genes, each gene corresponds to a shRNA-miR expression frame, and then seamlessly connected;

c. Constitutive shRNA-miR plasmids with different resistance genes, only the resistance genes are different, and other sequences are the same;

d, M base represents A or C base, N represents A, T, G, C base;

e. If N1 is a G base, then M1 is an A base; otherwise, M1 is a C base;

f. The M1 base is complementary to the M2 base.

1.8 Gene editing system, gene editing method and testing method

1. Gene editing system

The gene editing technology of this patent adopts the CRISPR-Cas9 gene editing system. The Cas 9 protein used is Cas9(D10A), Cas 9(D10A) binds to sgRNA, sgRNA is responsible for specific recognition of the target sequence (genomic DNA), and then Cas 9(D10A) performs single-stranded cleavage of the target sequence. Genomic DNA double-strand break (DNA Double Strand Break, DSB), there must be two sets of Cas 9 (D10A)/sgRNA to cut the two strands of genomic DNA, and the cutting distance should not be too far. The advantages of Cas 9(D10A)/sgRNA protocol compared with Cas 9/sgRNA protocol are higher specificity and lower probability of off-target. The plasmids or Donor fragments used in this gene editing system are: Cas9 (D10A) plasmid, sgRNA clone plasmid, and Donor fragment, respectively.

(1) Cas9 (D10A) plasmid: a plasmid expressing Cas 9 (D10A) protein, which specifically cuts genomic DNA under the guidance of sgRNA.

(2) sgRNA plasmid: a plasmid expressing sgRNA, sgRNA (small guide RNA) is a guide RNA (guideRNA, gRNA), which is responsible for guiding the targeted cleavage of the expressed Cas 9 (D10A) protein in gene editing.

(3) Donor fragment: the two ends contain recombination arms, which are located on the left and right sides of the genomic DNA break position, and the middle contains the gene, fragment or expression element to be inserted. In the presence of Donor fragments, cells undergo a homologous recombination (HR) reaction at the site of genome breakage. If the Donor fragment is not added, the non-homologous end joining (NHEJ) reaction occurs at the genomic break site of the cell. The fragment was recovered after digestion with KI Vector plasmid.

2. Constitutive and inducible plasmids

Constitutive plasmid: Donor fragment obtained from constitutive plasmid, after knocking in genomic DNA, the expression function of this fragment cannot be regulated.

Inducible plasmid: After the Donor fragment obtained from the inducible plasmid is knocked into the genomic DNA, the expression function of the fragment can be regulated by adding an inducer, which is equivalent to adding an on or off switch to the expression function.

3. Plasmid construction method

(1) Cas9 (D10A) plasmid. This plasmid no longer required construction and was ordered directly from Addgene (Plasmid 1816, Addgene).

(2) sgRNA plasmid. The original blank plasmid was ordered from Addgene (Plasmid 41824, Addgene), and then the target sequence was designed by inputting the DNA sequence on the website (URL: https://cctop.cos.uni-heidelberg.de), and finally the different target sequences were put into A blank sgRNA plasmid completes the construction.

(3) KI (Knock-in) Vector plasmid.

a. Acquisition of Amp(R)-pUC origin fragment. PCR primers were designed, and the fragment was amplified and recovered by PCR using a high-fidelity enzyme (Nanjing Novozymes, P505-d1) using the pUC18 plasmid as a template.

b. Acquisition of AAVS1 or eGSH recombination arm. The genomic DNA of human cells was extracted and the corresponding primers were designed, and then the human genomic DNA was used as a template to amplify and recover such fragments by PCR using a high-fidelity enzyme (Nanjing Novozymes, P505-d1).

c. Acquisition of individual plasmid elements. PCR amplification primers for each element were designed, and then each plasmid element was amplified and recovered by PCR using the plasmid containing the element as a template using a high-fidelity enzyme (Nanjing Novozymes, P505-d1).

d. Assembly into complete plasmids. Use multi-fragment recombinase (Nanjing Novozymes, C113-02) to connect the fragments obtained in the previous step to form a complete plasmid.

The process of gene editing

1. Single-cell cloning operation steps for AAVS1 gene knock-in

(1) Electric transfer procedure:

Donor Cell Preparation: Human Pluripotent Stem Cells

Kit 1Kit: Human Stem Cell

Kit 1

Instrument: Electroporator

Medium: BioCISO

Induction plasmid: Cas9D10A, sgRNA clone AAVS1-1, sgRNA clone AAVS1-2, AAVS1 neoVectoⅠ, AAVS1 neo VectorⅡ

Note: The induction plasmids used for eGSH gene knock-in: Cas9D10A, sgRNA clone eGSH-1, sgRNA clone eGSH-2, eGSH-neo/eGSH-puro (donor) The donor plasmid here is compared with AAVS1, only the left and right recombination arms are different. All other components are the same. Since the gene editing process of eGSH is the same as that of AAVS1, it will not be repeated later.

(2) The electrotransformed human pluripotent stem cells were screened in double antibiotic medium containing G418 and puro

(3) Screening and culturing single-cell clones to obtain single-cell clones.

2. AAVS1 gene knock-in single-cell clone culture reagent

(1) Medium: BioCISO+300μg/ml G418+0.5μg/ml puro

(It should be placed at room temperature in advance and placed in the dark for 30-60 minutes until it returns to room temperature. Note: BioCISO should not be preheated at 37°C to avoid the reduction of biomolecular activity.)

(2) Matrigel: hESC grade Matrigel

(Before passaging or resuscitating cells, add the Matrigel working solution to the cell culture flask and shake well to ensure that the Matrigel completely covers the bottom of the culture flask, and that the Matrigel cannot be dried anywhere before use. In order to ensure that the cells can be better For adherence and survival, Matrigel is placed in a 37°C incubator. Packing time: 1:100X Matrigel should not be less than 0.5 hours; 1:200X Matrigel should not be less than 2 hours.)

(3) Digestion solution: dissolve EDTA in DPBS to a final concentration of 0.5 mM, pH 7.4

(Note: EDTA cannot be diluted with water, otherwise cells will die due to reduced osmotic pressure.)

(4) Freezing medium: 60% BioCISO+30% ESCs grade FBS+10% DMSO

(The cryopreservation solution is best prepared and used immediately.)

3. Routine Maintenance Subculture Process

(1) The best time for passage and passage ratio

a. The best time for passage: the overall confluence of cells reaches 80% to 90%.

b. The optimal ratio of passage: 1:4～1:7 passage, and the best confluence the next day should be maintained at 20%～30%.

(2) Passaging process

a. Aspirate and discard the Matrigel in the coated cell culture flask in advance, add an appropriate amount of medium (BioCISO+300μg/ml G418+0.5μg/ml puro), and put it into a 37°C, 5% CO2 incubator incubate;

b. When the cells meet the requirements of passage, aspirate the medium supernatant, and add an appropriate amount of 0.5mM EDTA digestion solution to the cell flask dish;

c. Put the cells into a 37°C, 5% CO2 incubator and incubate for 5-10 minutes (digested until most of the cells are shrunk and rounded but have not floated under the microscope, gently blow the cells to detach them from the wall, Aspirate the cell suspension into a centrifuge tube and centrifuge at 200g for 5 minutes;

d. After centrifugation, discard the supernatant, resuspend the cells with medium, gently pipette the cells several times to mix well, and then transfer the cells to a bottle prepared to be coated with Matrigel;

e. After the cells are transferred to the cell flask dish, shake them horizontally from front to back and left and right. After no abnormality is observed under the microscope, shake well and place them in a 37°C, 5% CO2 incubator for culture;

f. Observe the cell adherent survival state the next day, aspirate the medium and change the medium on time every day.

4. Cell cryopreservation

(1) According to the routine passaging procedure, digest the cells with 0.5mM EDTA until most of the cells shrink and become round but have not floated, gently pipet the cells, collect the cell suspension, centrifuge at 200g for 5 minutes, discard the supernatant, and add an appropriate amount of freezing solution Resuspend the cells and transfer the cells to a cryopreservation tube (it is recommended to freeze one tube at a confluence of 80% of the six-well plate, and the volume of the cryopreservation solution is 0.5ml/tube);

(2) Place the cryovials in a programmed cooling box, and immediately put them at -80°C overnight (the temperature of the cryopreservation tube must be lowered by 1°C per minute);

(3) The cells were immediately transferred into liquid nitrogen the next day.

5. Cell Recovery

(1) Prepare the Matrigel-coated cell flask dish in advance. Before resuscitating the cells, aspirate the Matrigel, add an appropriate amount of BioCISO to the cell flask dish, and incubate in a 37°C, 5% CO2 incubator;

(2) Quickly take out the cryopreservation tube from the liquid nitrogen, and immediately put it into a 37°C water bath and shake it quickly to thaw the cells quickly. After careful observation, stop shaking when the ice crystals completely disappear, and transfer the cells to a biological safety cabinet;

(3) Add 10ml of DMEM/F12 (1:1) basal medium to a 15ml centrifuge tube in advance, and equilibrate to room temperature. Use a Pasteur pipette to pipette 1ml of DMEM/F12 (1:1) and slowly add it to the cryopreservation tube, mix gently. Homogenize, transfer the cell suspension to a prepared 15ml centrifuge tube containing DMEM/F12 (1:1), and centrifuge at 200g for 5 minutes;

(4) Carefully discard the supernatant, add an appropriate amount of BioCISO, gently mix the cells, and plant them in the prepared cell flask dish. , 5% CO2 incubator;

(5) Observe the cell adherent survival state the next day, and change the medium regularly every day. If the adherence is good, the BioCISO is replaced with BioCISO+300μg/ml G418+0.5μg/ml puro.

5. AAVS1 gene knock-in detection method

1. Single-cell clone AAVS1 gene knock-in assay

(1) Description of AAVS1 gene knock-in detection

a. Test purpose: PCR detection of gene knock-in-treated cells to test whether the cells are homozygous. Since the two Donor fragments only have differences in the sequence of the resistance gene, to determine whether the cell is homozygous (two chromosomes knock-in the Donor fragments of different resistance genes respectively), it is necessary to detect whether the genome of the cell contains two genes. The Donor fragment of the resistance gene, only double knock-in cells may be correct homozygous;

b. Test method: firstly design a primer inside Donor plasmid (non-recombination arm part), and then design another primer in genome PPP1R12C (non-recombination arm part). If the Donor fragment can be inserted correctly in the genome, there will be a target band, otherwise no target band will appear;

c. Test protocol primer sequences and PCR protocol are shown in Table 4:

Table 4 Test protocol primer sequences and PCR protocol

Note: The detection method of eGSH gene knock-in is the same as the principle and method of AAVS1 gene knock-in detection, and will not be described here.

2 Detection methods

2.2.1. Detection of IL-2 expression in pluripotent stem cell derivatives expressing IL-2

The ability of pluripotent stem cells and their derivatives to express IL-2 was determined by IL-2 ELISA detection kit. Collect the culture supernatant of IL-2-expressing pluripotent stem cells and their derivatives, and load them on an enzyme-labeled plate. Add 40 ul of sample diluent to the wells of the samples to be tested, and then add 10 ul of the sample to be tested. For the control group, add no The culture supernatant of IL-2-expressing pluripotent stem cells and their derivatives was mixed gently. After sealing, the plate was incubated at 37°C for 30min, washed 5 times, and then added 50ul of enzyme labeling reagent. After sealing, the plate was incubated at 37°C for 30min. After washing for 5 times, add chromogenic solution for color development for 15min, and add 50ul of stop solution. The reading measures the absorbance value at 450 nm.

2.2.2 MTT assay to detect the effect of expressed IL-2 on the proliferation of NK cells

Preparation of NK cells: NK cells were isolated by sorting using the MagniSort ^™ Human NK cell Enrichment Kit (Invitrogen ^™ , Cat. No. 8804-6819-74). The cells were resuspended in the medium containing the supernatant of the IL-2-expressing pluripotent stem cell medium, and the cells were counted by trypan blue staining. Each well was seeded with 3000 cells, 5 replicate wells, and then supplemented with medium (containing IL-2-expressing pluripotent stem cell medium supernatant) to a final volume of 150uL, and the corresponding medium was replaced every day, and the cells were placed in 37 The MTT value was measured after culturing for 48 h in a 5% CO ₂ incubator.

2.2.3. Mouse tumor therapy

In humanized NSG mice (The Jackson Laboratory (JAX)), 5×10 ⁶ tumor cells (RCC kidney cancer, MC colon cancer, NIC lung cancer) were subcutaneously injected into the right axilla, and the tumors grew to 60 mm ³ Tail vein injection of 200 uL PBS (containing human immune cells and 1×10 ⁶ IL-2-expressing pluripotent stem cell derivatives) was performed for tumor treatment, in which only the group containing human immune cells was injected as a control group. After 20 days, the mice were sacrificed, and then the tumor size between the groups was compared and the statistical analysis of differences was performed.

3 Experimental protocols

The experimental protocols for knocking IL-2, one or more immune-compatible molecules, shRNA and/or miRNA processing complex-related genes, and anti-interferon effector molecules into safe sites in the genome of pluripotent stem cells are shown in Table 5 and Table 6. , where "+" sign indicates gene or nucleic acid sequence knock-in, and "-" sign indicates gene knock-out.

Table 5 Experimental protocol for constitutive expression

The selected plasmids and the specific knock-in principles are as follows:

General principle: IL-2 expression sequence is placed in the position of MCS2 of the corresponding plasmid, shRNA is placed in the shRNA expression frame of the corresponding plasmid, shRNAmiR is placed in the shRNAmiR expression frame of the corresponding plasmid, and other genes are placed in the position of MCS1 of the corresponding plasmid.

Note: The sgRNA clone B2M plasmid contains the sgRNA clone B2M-1 and sgRNA clone B2M-2 plasmids. The sgRNA clone CIITA plasmid contains the sgRNA clone CIITA-1 and sgRNA clone CIITA-2 plasmids.

(1) Group A1:

The MCS2 of the AAVS1 KI Vector (shRNA, constitutive) plasmid is put into the IL-2 expression sequence, and the MCS1 is put into other gene sequences (if there are multiple genes, EMCV IRESwt (SEQ ID NO. 178, the same below) is used to connect them).

(2) Group A2:

The MCS2 of the AAVS1 KI Vector (shRNA-miR, constitutive) plasmid was put into the IL-2 expression sequence. The shRNA expression framework is placed into the shRNA target sequence (seamlessly linked if multiple shRNAs are present). MCS1 was placed into other gene sequences (connected using EMCV IRESwt if multiple genes were present).

(3) Group A3:

The MCS2 of the AAVS1 KI Vector (shRNA-miR, constitutive) plasmid was put into the IL-2 expression sequence. The shRNA-miR expression framework is placed into the shRNA-miR target sequence (seamlessly linked if multiple shRNA-miRs are present). MCS1 was placed into other gene sequences (connected using EMCV IRESwt if multiple genes were present).

(4) A4 grouping:

The MCS2 of the AAVS1 KI Vector (shRNA, constitutive) plasmid was placed into the IL-2 expression sequence. MCS1 was placed into other gene sequences (connected using EMCV IRESwt if multiple genes were present).

The target sequence of the sgRNA clone B2M plasmid is put into the sgRNA target sequence of B2M:

sgRNA-B2M-1: CGCGAGCACAGCTAAGGCCACGG (SEQ ID NO. 179),

sgRNA-B2M-2: ACTCTCTCTTTCTGGCCTGGAGG (SEQ ID NO. 180).

The target sequence of the sgRNA clone CIITA plasmid is put into the sgRNA target sequence of CIITA:

sgRNA-CIITA-1: ACCCAGCAGGGCGTGGAGCCAGG (SEQ ID NO. 181)

sgRNA-CIITA-2: GTCAGAGCCCCAAGGTAAAAAGG (SEQ ID NO. 182).

(5) A5 grouping: (same method as A2 grouping)

(6) A6 grouping: (same method as A3 grouping)

Table 6 Inducible expression (immunocompatible and reversible) experimental protocol

(1) Group B1:

The MCS2 of the AAVS1 KI Vector (shRNA, inducible) plasmid was put into the IL-2 expression sequence. The shRNA expression framework is placed into the shRNA target sequence (seamlessly linked if multiple shRNAs are present). MCS1 was placed into other gene sequences (connected using EMCV IRESwt if multiple genes were present).

(2) Group B2:

The MCS2 of the AAVS1 KI Vector (shRNA-miR, inducible) plasmid was put into the IL-2 expression sequence. The shRNA-miR expression framework is placed into the shRNA target sequence (seamlessly linked if multiple shRNA-miRs are present). MCS1 was placed into other gene sequences (connected using EMCV IRESwt if multiple genes were present).

(3) B3 grouping: (same method as B1 grouping).

(4) B4 grouping: (same method as B2 grouping).

4 Experimental results

4.1 ELISA to detect the expression of IL-2

The ability of pluripotent stem cells and their derivatives to express IL-2 was determined by IL-2 ELISA detection kit. Collect the culture supernatant of IL-2-expressing pluripotent stem cells and their derivatives, load the sample onto the microtiter plate, add 40ul of the sample diluent to the well of the sample to be tested, then add 10ul of the sample to be tested, while the control group does not add 40ul of the sample diluent. The culture supernatant of IL-2-expressing pluripotent stem cells and their derivatives was mixed gently. After sealing, the plate was incubated at 37 °C for 30 min, washed 5 times, and then added 50 ul of enzyme labeling reagent. After sealing, the plate was incubated at 37 °C for 30 min. After washing 5 times, add the color developing solution for 15 min, and add 50 ul of stop solution. The reading measures the absorbance value at 450 nm.

Table 7 ELISA detection of IL-2 expressed in each experimental group

As can be seen from the above table, the expression of IL-2 expressed by the pluripotent stem cells or derivatives thereof of the present invention can be relatively constant in each group, so the IL-2 expressed by the pluripotent stem cell derivatives is not affected by cell differentiation morphology and Influenced by other foreign genes (immunocompatible modification).

4.2 The effect of IL-2-expressing pluripotent stem cells or their derivatives on promoting NK cell proliferation

The protocols of each experimental group in Tables 5 and 6 were knocked into the genomic safety site AAVS1 of iPSCs, MSCs, NSCs, and EBs cells to obtain cells expressing IL-2. Using MTT method to detect its effect on promoting NK cell proliferation:

Table 8 Effects of IL-2 expressed in each experimental group on the proliferation of NK cells

Through the above experiments, it can be proved that the IL-2-expressing stem cells or derivatives thereof prepared by the present invention can effectively stimulate NK cells to proliferate.

4.3 Antitumor effect of IL-2-expressing pluripotent stem cells or their derivatives

In the humanized NSG mouse tumor model, the inventors injected hPSCs and hPSCs-derived derivatives (hPSCs-MSCs, hPSCs-NSCs, hPSCs-EBs) capable of expressing IL-2 (anti-CD28 antibody), and observed the The effect of tumor therapy on RCC kidney cancer, MC colon cancer, and NIC lung cancer, only the group containing human immune cells was injected as a control group. Note: In order to avoid the problem of immune compatibility, the immune cells used by the inventors and hPSCs and hPSCs-derived derivatives are all derived from the same person, and the immune compatibility scheme of B2M and CIITA gene knockout is adopted. The experimental results are shown in the table below. The N (control) group refers to the NSG mouse tumor model that was not injected with the experimental cells.

Table 9 Tumor therapy of IL-2-expressing pluripotent stem cells or derivatives thereof

Through the above experiments, it can be proved that the IL-2-expressing stem cells or their derivatives prepared by the present invention can effectively stimulate the proliferation of NK cells and play an anti-tumor effect.

4.4 Reversible expression test of immune-compatible molecular-inducible expression panel

Through the above examples, hPSCs and hPSCs-derived derivatives expressing IL-2 can effectively express IL-2 and thus play an anti-tumor effect. The immunocompatibility of hPSCs and hPSCs-derived derivatives must also be considered. Therefore, a suitable combination was selected to test the immune compatibility.

Taking advantage of the low immunogenicity of MSCs, the humanized NSG mouse tumor model was injected with hPSCs-derived immune-compatible MSCs expressing IL-2 to observe the effect of tumor (NIC lung cancer) therapy. Note: The immune cells and hPSCs-derived MSCs used are not from the same person.

The control group refers to the NSG mouse tumor model without MSCs injection.

The treatment of the Dox-added group was as follows: 0.5 mg/mL Dox was added to the mouse diet, and the mice were fed, starting from the injection of the expression cells, and used until the end of the experiment.

Table 10 The reversible expression test results of the immune-compatible molecule-inducible expression group

The above experiments showed that: MSCs expressing only IL-2 (group 2) have low immunogenicity and can exist in the allogene for a certain period of time, so they can exert a certain tumor therapeutic effect, while the immunocompatibility transformation (group 3) -11, including constitutive and reversible inducible immune compatibility), its immune compatibility effect is better, and it can exist in the body for a longer time (or can achieve long-term coexistence) than MSCs without immune compatibility modification. The group 5 is the B2M and CIITA gene knockout group, which completely eliminates the effects of HLA-I and HLA-II molecules, so its tumor treatment effect is the best. However, due to its constitutive immune-compatible modification (gene knock-in/knock-out), it cannot be cleared when the graft is mutated or not needed, so there is a group 8-15 protocol setting. In Groups 12-15, when IL-2-expressing cells were injected into mice, the Dox inducer (always used) was used in mice, and the immune-compatibility effect of mice injected with IL-2-expressing cells was eliminated, which was in The existence time in vivo is comparable to that of MSCs without immune-compatibility modification, and its tumor treatment effect is also comparable to that of MSCs without immune-compatibility modification.

The above embodiments are only preferred cases of the present invention, and those skilled in the art can understand that: without departing from the principle and purpose of the present invention, the modifications and replacements of the equivalent effects carried out by these embodiments all fall within the scope of the present invention. The scope of protection of the invention claims.

SEQUENCE LISTING

<110> Future Homo sapiens Regenerative Medicine Research Institute (Guangzhou) Co., Ltd.; Wang Linli

<120> A pluripotent stem cell derivative expressing IL-2 and its application

<130>

<160> 183

<170> PatentIn version 3.5

<210> 1

<211> 399

<212> DNA

<213> human

<400> 1

gcacctactt caagttctac aaagaaaaca cagctacaac tggagcattt actgctggat 60

ttacagatga ttttgaatgg aattaataat tacaagaatc ccaaactcac caggatgctc 120

acatttaagt tttacatgcc caagaaggcc acagaactga aacatcttca gtgtctagaa 180

gaagaactca aacctctgga ggaagtgcta aatttagctc aaagcaaaaa ctttcactta 240

agacccaggg acttaatcag caatatcaac gtaatagttc tggaactaaa gggatctgaa 300

acaacattca tgtgtgaata tgctgatgag acagcaacca ttgtagaatt tctgaacaga 360

tggattacct tttgtcaaag catcatctca acactgact 399

<210> 2

<211> 21

<212> DNA

<213> human

<400> 2

gggagcagag aattctctta t 21

<210> 3

<211> 21

<212> DNA

<213> human

<400> 3

ggagcagaga attctcttat c 21

<210> 4

<211> 21

<212> DNA

<213> human

<400> 4

gagcagagaa ttctcttatc c 21

<210> 5

<211> 21

<212> DNA

<213> human

<400> 5

gctacctgga gcttcttaac a 21

<210> 6

<211> 21

<212> DNA

<213> human

<400> 6

ggagcttctt aacagcgatg c 21

<210> 7

<211> 21

<212> DNA

<213> human

<400> 7

gggtctccag tatattcatc t 21

<210> 8

<211> 21

<212> DNA

<213> human

<400> 8

gcctcctgat gcacatgtac t 21

<210> 9

<211> 21

<212> DNA

<213> human

<400> 9

ggaagacctg ggaaagcttg t 21

<210> 10

<211> 21

<212> DNA

<213> human

<400> 10

ggctaagctt gtacaataac t 21

<210> 11

<211> 21

<212> DNA

<213> human

<400> 11

gcggaatgaa ccacatcttg c 21

<210> 12

<211> 21

<212> DNA

<213> human

<400> 12

ggccttctct gaaggacatt g 21

<210> 13

<211> 21

<212> DNA

<213> human

<400> 13

ggactcaatg cactgacatt g 21

<210> 14

<211> 21

<212> DNA

<213> human

<400> 14

ggtacccact gctctggtta t 21

<210> 15

<211> 21

<212> DNA

<213> human

<400> 15

gctcccactc catgaggtat t 21

<210> 16

<211> 21

<212> DNA

<213> human

<400> 16

ggtatttctt cacatccgtg t 21

<210> 17

<211> 21

<212> DNA

<213> human

<400> 17

aggagacacg gaatgtgaag g 21

<210> 18

<211> 21

<212> DNA

<213> human

<400> 18

gctcccactc catgaggtat t 21

<210> 19

<211> 21

<212> DNA

<213> human

<400> 19

ggtatttcta cacctccgtg t 21

<210> 20

<211> 21

<212> DNA

<213> human

<400> 20

ggaccggaac acacagatct a 21

<210> 21

<211> 21

<212> DNA

<213> human

<400> 21

accggaacac acagatctac a 21

<210> 22

<211> 21

<212> DNA

<213> human

<400> 22

ggaacacaca gatctacaag g 21

<210> 23

<211> 21

<212> DNA

<213> human

<400> 23

gaacacacag atctacaagg c 21

<210> 24

<211> 21

<212> DNA

<213> human

<400> 24

ttcttacttc cctaatgaag t 21

<210> 25

<211> 21

<212> DNA

<213> human

<400> 25

aagttaagaa cctgaatata a 21

<210> 26

<211> 21

<212> DNA

<213> human

<400> 26

aacctgaata taaatttgtg t 21

<210> 27

<211> 21

<212> DNA

<213> human

<400> 27

acctgaatat aaatttgtgt t 21

<210> 28

<211> 21

<212> DNA

<213> human

<400> 28

aagcgttgat ggattaatta a 21

<210> 29

<211> 21

<212> DNA

<213> human

<400> 29

agcgttgatg gattaattaa a 21

<210> 30

<211> 21

<212> DNA

<213> human

<400> 30

gggtctggtg ggcatcatta t 21

<210> 31

<211> 21

<212> DNA

<213> human

<400> 31

ggtctggtgg gcatcattat t 21

<210> 32

<211> 21

<212> DNA

<213> human

<400> 32

gcatcattat tgggaccatc t 21

<210> 33

<211> 21

<212> DNA

<213> human

<400> 33

gcacatggag gtgatggtgt t 21

<210> 34

<211> 21

<212> DNA

<213> human

<400> 34

ggaggtgatg gtgtttctta g 21

<210> 35

<211> 21

<212> DNA

<213> human

<400> 35

gagaagatca ctgaagaaac t 21

<210> 36

<211> 21

<212> DNA

<213> human

<400> 36

gctttaatgg ctttacaaag c 21

<210> 37

<211> 21

<212> DNA

<213> human

<400> 37

ggctttacaa agctggcaat a 21

<210> 38

<211> 21

<212> DNA

<213> human

<400> 38

gctttacaaa gctggcaata t 21

<210> 39

<211> 21

<212> DNA

<213> human

<400> 39

gctccgtact ctaacatcta g 21

<210> 40

<211> 21

<212> DNA

<213> human

<400> 40

gatgaccaca ttcaaggaag a 21

<210> 41

<211> 21

<212> DNA

<213> human

<400> 41

gaccacattc aaggaagaac t 21

<210> 42

<211> 21

<212> DNA

<213> human

<400> 42

gctttcctgc ttggcagtta t 21

<210> 43

<211> 21

<212> DNA

<213> human

<400> 43

ggcagttatt cttccacaag a 21

<210> 44

<211> 21

<212> DNA

<213> human

<400> 44

gcagttattc ttccacaaga g 21

<210> 45

<211> 21

<212> DNA

<213> human

<400> 45

gcgtaagtct gagtgtcatt t 21

<210> 46

<211> 21

<212> DNA

<213> human

<400> 46

gacaatttaa ggaagaatct t 21

<210> 47

<211> 21

<212> DNA

<213> human

<400> 47

ggccatagtt ctccctgatt g 21

<210> 48

<211> 21

<212> DNA

<213> human

<400> 48

gccatagttc tccctgattg a 21

<210> 49

<211> 21

<212> DNA

<213> human

<400> 49

gcagatgacc acattcaagg a 21

<210> 50

<211> 21

<212> DNA

<213> human

<400> 50

gatgaccaca ttcaaggaag a 21

<210> 51

<211> 21

<212> DNA

<213> human

<400> 51

gaccacattc aaggaagaac c 21

<210> 52

<211> 21

<212> DNA

<213> human

<400> 52

gctttgtcag gaccaggttg t 21

<210> 53

<211> 21

<212> DNA

<213> human

<400> 53

gaccaggttg ttactggttc a 21

<210> 54

<211> 21

<212> DNA

<213> human

<400> 54

gaagcctcac agctttgatg g 21

<210> 55

<211> 21

<212> DNA

<213> human

<400> 55

gatggcagtg cctcatcttc a 21

<210> 56

<211> 21

<212> DNA

<213> human

<400> 56

ggcagtgcct catcttcaac t 21

<210> 57

<211> 21

<212> DNA

<213> human

<400> 57

gcagcaggat aagtatgagt g 21

<210> 58

<211> 21

<212> DNA

<213> human

<400> 58

gcaggataag tatgagtgtc a 21

<210> 59

<211> 21

<212> DNA

<213> human

<400> 59

ggttcctgca cagagacatc t 21

<210> 60

<211> 21

<212> DNA

<213> human

<400> 60

gcacaagagac atctataacc a 21

<210> 61

<211> 21

<212> DNA

<213> human

<400> 61

gagacatcta taaccaagag g 21

<210> 62

<211> 21

<212> DNA

<213> human

<400> 62

gagtactgga acagccagaa g 21

<210> 63

<211> 21

<212> DNA

<213> human

<400> 63

gctttcctgc ttggctctta t 21

<210> 64

<211> 21

<212> DNA

<213> human

<400> 64

ggctcttatt cttccacaag a 21

<210> 65

<211> 21

<212> DNA

<213> human

<400> 65

gctcttattc ttccacaaga g 21

<210> 66

<211> 21

<212> DNA

<213> human

<400> 66

ggatgtggaa cccacagata c 21

<210> 67

<211> 21

<212> DNA

<213> human

<400> 67

gatgtggaac ccacagatac a 21

<210> 68

<211> 21

<212> DNA

<213> human

<400> 68

gtggaaccca cagatacaga g 21

<210> 69

<211> 21

<212> DNA

<213> human

<400> 69

ggaacccaca gatacagaga g 21

<210> 70

<211> 21

<212> DNA

<213> human

<400> 70

gagccaactg tattgcctat t 21

<210> 71

<211> 21

<212> DNA

<213> human

<400> 71

agccaactgt attgcctatt t 21

<210> 72

<211> 21

<212> DNA

<213> human

<400> 72

gccaactgta ttgcctattt g 21

<210> 73

<211> 21

<212> DNA

<213> human

<400> 73

gggtagcaac tgtcaccttg a 21

<210> 74

<211> 21

<212> DNA

<213> human

<400> 74

ggatttcgtg ttccagttta a 21

<210> 75

<211> 21

<212> DNA

<213> human

<400> 75

gcatgtgcta cttcaccaac g 21

<210> 76

<211> 21

<212> DNA

<213> human

<400> 76

gcgtcttgtg accagataca t 21

<210> 77

<211> 21

<212> DNA

<213> human

<400> 77

gcttatgcct gcccagaatt c 21

<210> 78

<211> 21

<212> DNA

<213> human

<400> 78

gcaggaaatc actgcagaat g 21

<210> 79

<211> 21

<212> DNA

<213> human

<400> 79

gctcagtgca ttggccttag a 21

<210> 80

<211> 21

<212> DNA

<213> human

<400> 80

ggtgagtgct gtgtaaataa g 21

<210> 81

<211> 21

<212> DNA

<213> human

<400> 81

gacatatata gtgatccttg g 21

<210> 82

<211> 21

<212> DNA

<213> human

<400> 82

ggaaagtcac atcgatcaag a 21

<210> 83

<211> 21

<212> DNA

<213> human

<400> 83

gctcacagtc atcaattata g 21

<210> 84

<211> 21

<212> DNA

<213> human

<400> 84

gccctgaaga cagaatgttc c 21

<210> 85

<211> 21

<212> DNA

<213> human

<400> 85

gcggaccatg tgtcaactta t 21

<210> 86

<211> 21

<212> DNA

<213> human

<400> 86

ggaccatgtg tcaacttatg c 21

<210> 87

<211> 21

<212> DNA

<213> human

<400> 87

gcgtttgtac agacgcatag a 21

<210> 88

<211> 21

<212> DNA

<213> human

<400> 88

ggctggctaa cattgctata t 21

<210> 89

<211> 21

<212> DNA

<213> human

<400> 89

gctggctaac attgctatat t 21

<210> 90

<211> 21

<212> DNA

<213> human

<400> 90

ggaccaggtc acatgtgaat a 21

<210> 91

<211> 21

<212> DNA

<213> human

<400> 91

ggaaaggtct gaggatattg a 21

<210> 92

<211> 21

<212> DNA

<213> human

<400> 92

ggcagattag gattccattc a 21

<210> 93

<211> 21

<212> DNA

<213> human

<400> 93

gcctgatagg acccatattc c 21

<210> 94

<211> 21

<212> DNA

<213> human

<400> 94

gcatccaata gacgtcattt g 21

<210> 95

<211> 21

<212> DNA

<213> human

<400> 95

gcgtcactgg cacagatata a 21

<210> 96

<211> 21

<212> DNA

<213> human

<400> 96

gctgtcacat aataagctaa g 21

<210> 97

<211> 21

<212> DNA

<213> human

<400> 97

gctaaggaag acagtatata g 21

<210> 98

<211> 21

<212> DNA

<213> human

<400> 98

gggatttcta aggaaggatg c 21

<210> 99

<211> 21

<212> DNA

<213> human

<400> 99

ggagttgaag agcagagatt c 21

<210> 100

<211> 21

<212> DNA

<213> human

<400> 100

gccagtgaac acttaccata g 21

<210> 101

<211> 21

<212> DNA

<213> human

<400> 101

gcttctctga agtctcattg a 21

<210> 102

<211> 21

<212> DNA

<213> human

<400> 102

ggctgcaact aacttcaaat a 21

<210> 103

<211> 21

<212> DNA

<213> human

<400> 103

ggatggattt gattatgatc c 21

<210> 104

<211> 21

<212> DNA

<213> human

<400> 104

ggaccttgga acaatggatt g 21

<210> 105

<211> 21

<212> DNA

<213> human

<400> 105

gctaattctt gctgaacttc t 21

<210> 106

<211> 21

<212> DNA

<213> human

<400> 106

gctgaacttc ttcatgtatg t 21

<210> 107

<211> 21

<212> DNA

<213> human

<400> 107

gcctcatctc tttgttctaa a 21

<210> 108

<211> 21

<212> DNA

<213> human

<400> 108

gctctggaga agatatattt g 21

<210> 109

<211> 21

<212> DNA

<213> human

<400> 109

gctcttgagg gaactaatag a 21

<210> 110

<211> 21

<212> DNA

<213> human

<400> 110

gggacggcat taatgtattc a 21

<210> 111

<211> 21

<212> DNA

<213> human

<400> 111

ggacaaacat gcaaactata g 21

<210> 112

<211> 21

<212> DNA

<213> human

<400> 112

gcagcaacca gctaccattc t 21

<210> 113

<211> 21

<212> DNA

<213> human

<400> 113

gcagttctgt tgccactctc t 21

<210> 114

<211> 21

<212> DNA

<213> human

<400> 114

gggagagttc atccaggaaa t 21

<210> 115

<211> 21

<212> DNA

<213> human

<400> 115

ggagagttca tccaggaaat t 21

<210> 116

<211> 21

<212> DNA

<213> human

<400> 116

gagagttcat ccaggaaatt a 21

<210> 117

<211> 21

<212> DNA

<213> human

<400> 117

gcctgtcaaa gagagagagc a 21

<210> 118

<211> 21

<212> DNA

<213> human

<400> 118

gctcagcttc gtactgagtt c 21

<210> 119

<211> 21

<212> DNA

<213> human

<400> 119

gcttcacaga actacagaga g 21

<210> 120

<211> 21

<212> DNA

<213> human

<400> 120

gcatctactg gacaaagtat t 21

<210> 121

<211> 21

<212> DNA

<213> human

<400> 121

ggctgaatta cccatgcttt a 21

<210> 122

<211> 21

<212> DNA

<213> human

<400> 122

gctgaattac ccatgcttta a 21

<210> 123

<211> 21

<212> DNA

<213> human

<400> 123

gggttggttt atccaggaat a 21

<210> 124

<211> 21

<212> DNA

<213> human

<400> 124

ggatcagaag agaagccaac g 21

<210> 125

<211> 21

<212> DNA

<213> human

<400> 125

ggttcaccat ccaggtgttc a 21

<210> 126

<211> 21

<212> DNA

<213> human

<400> 126

gctctcttct ctggaactaa c 21

<210> 127

<211> 21

<212> DNA

<213> human

<400> 127

gctagagtga ctccatctta a 21

<210> 128

<211> 21

<212> DNA

<213> human

<400> 128

gctgaccacc aattataatt g 21

<210> 129

<211> 21

<212> DNA

<213> human

<400> 129

gcagaatatt taaggccata c 21

<210> 130

<211> 21

<212> DNA

<213> human

<400> 130

gcccacttaa aggcagcatt a 21

<210> 131

<211> 21

<212> DNA

<213> human

<400> 131

ggtcatcaat accactgtta a 21

<210> 132

<211> 21

<212> DNA

<213> human

<400> 132

gcattcctcc ttctcctttc t 21

<210> 133

<211> 21

<212> DNA

<213> human

<400> 133

ggaggaactt tgtgaacatt c 21

<210> 134

<211> 21

<212> DNA

<213> human

<400> 134

gctgtaagaa ggatgctttc a 21

<210> 135

<211> 21

<212> DNA

<213> human

<400> 135

gctgcaggca ggattgtttc a 21

<210> 136

<211> 21

<212> DNA

<213> human

<400> 136

gcagttcgag gtcaagtttg a 21

<210> 137

<211> 21

<212> DNA

<213> human

<400> 137

gccaattagc tgagaagaat t 21

<210> 138

<211> 21

<212> DNA

<213> human

<400> 138

gcaggtttac agtgtatatg t 21

<210> 139

<211> 21

<212> DNA

<213> human

<400> 139

gcctacagag actagagtag g 21

<210> 140

<211> 21

<212> DNA

<213> human

<400> 140

gcagttgggt accttccatt c 21

<210> 141

<211> 21

<212> DNA

<213> human

<400> 141

gcaactcagg tgcatgatac a 21

<210> 142

<211> 21

<212> DNA

<213> human

<400> 142

gcatggcgct ggtacgtaaa t 21

<210> 143

<211> 19

<212> DNA

<213> human

<400> 143

gcctcgagtt tgagagcta 19

<210> 144

<211> 19

<212> DNA

<213> human

<400> 144

agacattctg gatgagtta 19

<210> 145

<211> 19

<212> DNA

<213> human

<400> 145

gggtctgtta cccaaagaa 19

<210> 146

<211> 19

<212> DNA

<213> human

<400> 146

ggtctgttac ccaaagaat 19

<210> 147

<211> 19

<212> DNA

<213> human

<400> 147

ggaaggaagc ggacgctca 19

<210> 148

<211> 19

<212> DNA

<213> human

<400> 148

ggaggcagta cttctgata 19

<210> 149

<211> 19

<212> DNA

<213> human

<400> 149

cgctctagag ctcagctga 19

<210> 150

<211> 19

<212> DNA

<213> human

<400> 150

ccaccacctc aaccaataa 19

<210> 151

<211> 19

<212> DNA

<213> human

<400> 151

atttcaagaa gtcgatcaa 19

<210> 152

<211> 19

<212> DNA

<213> human

<400> 152

gaagatctga ttaccttca 19

<210> 153

<211> 21

<212> DNA

<213> human

<400> 153

ggacactggt tcaacacctg t 21

<210> 154

<211> 21

<212> DNA

<213> human

<400> 154

ggttcaacac ctgtgacttc a 21

<210> 155

<211> 21

<212> DNA

<213> human

<400> 155

acctgtgact tcatgtgtgc g 21

<210> 156

<211> 21

<212> DNA

<213> human

<400> 156

gctggacgtg accatcatgt a 21

<210> 157

<211> 21

<212> DNA

<213> human

<400> 157

ggacgtgacc atcatgtaca a 21

<210> 158

<211> 21

<212> DNA

<213> human

<400> 158

gacgtgacca tcatgtacaa g 21

<210> 159

<211> 21

<212> DNA

<213> human

<400> 159

acgtgaccat catgtacaag g 21

<210> 160

<211> 21

<212> DNA

<213> human

<400> 160

acgctatacc atctacctgg g 21

<210> 161

<211> 21

<212> DNA

<213> human

<400> 161

gcctctatga cgacatcgag t 21

<210> 162

<211> 21

<212> DNA

<213> human

<400> 162

gacatcgagt gcttccttat g 21

<210> 163

<211> 253

<212> DNA

<213> human

<400> 163

gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgttagagag 60

ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120

aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180

atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 240

cgctagcgcc acc 253

<210> 164

<211> 9

<212> DNA

<213> human

<400> 164

ttcaagaga 9

<210> 165

<211> 686

<212> DNA

<213> human

<400> 165

gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgttagagag 60

ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120

aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180

atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 240

ctttaccact ccctatcagt gatagagaaa agtgaaagtc gagtttacca ctccctatca 300

gtgatagaga aaagtgaaag tcgagtttac cactccctat cagtgataga gaaaagtgaa 360

agtcgagttt accactccct atcagtgata gagaaaagtg aaagtcgagt ttaccactcc 420

ctatcagtga tagagaaaag tgaaagtcga gtttaccact ccctatcagt gatagagaaa 480

agtgaaagtc gagtttacca ctccctatca gtgatagaga aaagtgaaag tcgagctcgg 540

tacccgggtc gaggtaggcg tgtacggtgg gaggcctata taagcagagc tcgtttagtg 600

aaccgtcaga tcgcctggag acgccatcca cgctgttttg acctccatag aagacaccgg 660

gaccgatcca gcctgctagc gccacc 686

<210> 166

<211> 9

<212> DNA

<213> human

<400> 166

ttcaagaga 9

<210> 167

<211> 119

<212> DNA

<213> human

<400> 167

gaggcttcag tactttacag aatcgttgcc tgcacatctt ggaaacactt gctgggatta 60

cttcttcagg ttaacccaac agaaggctaa agaaggtata ttgctgttga cagtgagcg 119

<210> 168

<211> 19

<212> DNA

<213> human

<400> 168

tagtgaagcc acagatgta 19

<210> 169

<211> 119

<212> DNA

<213> human

<400> 169

tgcctactgc ctcggacttc aaggggctac tttaggagca attatcttgt ttactaaaac 60

tgaatacctt gctatctctt tgatacattt ttacaaagct gaattaaaat ggtataaat 119

<210> 170

<211> 22

<212> DNA

<213> human

<400> 170

ccatagctca gtctggtcta tc 22

<210> 171

<211> 22

<212> DNA

<213> human

<400> 171

tcaggatgat ctggacgaag ag 22

<210> 172

<211> 20

<212> DNA

<213> human

<400> 172

ccggtcctgg actttgtctc 20

<210> 173

<211> 20

<212> DNA

<213> human

<400> 173

ctcgacatcg gcaaggtgtg 20

<210> 174

<211> 20

<212> DNA

<213> human

<400> 174

cgcattggag tcgctttaac 20

<210> 175

<211> 24

<212> DNA

<213> human

<400> 175

cgagctgcaa gaactcttcc tcac 24

<210> 176

<211> 23

<212> DNA

<213> human

<400> 176

cacggcactt acctgtgttc tgg 23

<210> 177

<211> 23

<212> DNA

<213> human

<400> 177

cagtacaggc atccctgtga aag 23

<210> 178

<211> 53

<212> DNA

<213> human

<400> 178

cccctctccc tccccccccc ctaacgttac tggccgaagc cgcttggaat aaggccggtg 60

tgcgtttgtc tatatgttat tttccaccat attgccgtct tttggcaatg tgagggcccg 120

gaaacctggc cctgtcttct tgacgagcat tcctaggggt ctttcccctc tcgccaaagg 180

aatgcaaggt ctgttgaatg tcgtgaagga agcagttcct ctggaagctt cttgaagaca 240

aacaacgtct gtagcgaccc tttgcaggca gcggaacccc ccacctggcg acaggtgcct 300

ctgcggccaa aagccacgtg tataagatac acctgcaaag gcggcacaac cccagtgcca 360

cgttgtgagt tggatagttg tggaaagagt caaatggctc tcctcaagcg tattcaacaa 420

ggggctgaag gatgcccaga aggtacccca ttgtatggga tctgatctgg ggcctcggtg 480

cacatgcttt acatgtgttt agtcgaggtt aaaaaaacgt ctaggccccc cgaaccacgg 540

ggacgtggtt ttcctttgaa aaacacgatg ataatatggc cacaaccatg 590

<210> 179

<211> 23

<212> DNA

<213> human

<400> 179

cgcgagcaca gctaaggcca cgg 23

<210> 180

<211> 23

<212> DNA

<213> human

<400> 180

actctctctt tctggcctgg agg 23

<210> 181

<211> 23

<212> DNA

<213> human

<400> 181

acccagcagg gcgtggagcc agg 23

<210> 182

<211> 23

<212> DNA

<213> human

<400> 182

gtcagagccc caaggtaaaa agg 23

<210> 183

<211> 60

<212> DNA

<213> human

<400> 183

atgtacagga tgcaactcct gtcttgcatt gcactaagtc ttgcacttgt cacaaacagt 60

Claims (20)

1.A pluripotent stem cell or derivative thereof, wherein: the genome of the pluripotent stem cell or the derivative thereof is introduced with an expression sequence of IL-2.

2. The pluripotent stem cell or derivative thereof according to claim 1, wherein: the B2M gene and/or CIITA gene of the genome of the pluripotent stem cell or the derivative thereof is knocked out.

3. The pluripotent stem cell or derivative thereof according to claim 1, wherein: the genome of the pluripotent stem cell or the derivative thereof is also introduced with an expression sequence of at least one immune compatible molecule for regulating the expression of genes related to immune response in the pluripotent stem cell or the derivative thereof.

4. The pluripotent stem cell or derivative thereof according to claim 3, wherein: the genes associated with the immune response include:

(1) major histocompatibility complex genes including at least one of HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DQA1, HLA-DQB1, HLA-DPA1 and HLA-DPB 1;

(2) major histocompatibility complex-associated genes including at least one of B2M and CIITA.

5. The pluripotent stem cell or derivative thereof according to claim 3, wherein: the immune compatible molecule comprises:

(1) an immune tolerance-related gene including at least one of CD47 and HLA-G;

(2) HLA-C molecules, including HLA-C multiple alleles of which the proportion in the population is over 90 percent in total, or fusion protein genes consisting of the HLA-C multiple alleles of which the proportion is over 90 percent and B2M;

(3) shRNA and/or shRNA-miR targeting major histocompatibility complex genes including at least one of HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DQA1, HLA-DQB1, HLA-DPA1 and HLA-DPB 1;

(4) shRNA and/or shRNA-miR targeting a major histocompatibility complex-associated gene that includes at least one of B2M and CIITA.

6. The pluripotent stem cell or derivative thereof according to claim 5, wherein:

the target sequence of the shRNA and/or shRNA-miR of B2M is at least one of SEQ ID NO. 2-SEQ ID NO. 4;

the target sequence of the shRNA and/or shRNA-miR of the CIITA is at least one of SEQ ID NO. 5-SEQ ID NO. 14;

the target sequence of the shRNA and/or shRNA-miR of the HLA-A is at least one of SEQ ID NO. 15-SEQ ID NO. 17;

the target sequence of the shRNA and/or shRNA-miR of the HLA-B is at least one of SEQ ID NO. 18-SEQ ID NO. 23;

the target sequence of the shRNA and/or shRNA-miR of the HLA-C is at least one of SEQ ID NO. 24-SEQ ID NO. 29;

the target sequence of the shRNA and/or shRNA-miR of the HLA-DRA is at least one of SEQ ID NO. 30-SEQ ID NO. 39;

the target sequence of the shRNA and/or shRNA-miR of the HLA-DRB1 is at least one of SEQ ID NO. 40-SEQ ID NO. 44;

the target sequence of the shRNA and/or shRNA-miR of the HLA-DRB3 is at least one of SEQ ID NO. 45-SEQ ID NO. 46;

the target sequence of the shRNA and/or shRNA-miR of the HLA-DRB4 is at least one of SEQ ID NO. 47-SEQ ID NO. 56;

the target sequence of the shRNA and/or shRNA-miR of the HLA-DRB5 is at least one of SEQ ID NO. 57-SEQ ID NO. 65;

the target sequence of the shRNA and/or shRNA-miR of the HLA-DQA1 is at least one of SEQ ID NO. 66-SEQ ID NO. 72;

the target sequence of the shRNA and/or shRNA-miR of the HLA-DQB1 is at least one of SEQ ID NO. 73-SEQ ID NO. 82;

the target sequence of the shRNA and/or shRNA-miR of the HLA-DPA1 is at least one of SEQ ID NO. 83-SEQ ID NO. 92;

the target sequence of the shRNA and/or shRNA-miR of the HLA-DPB1 is at least one of SEQ ID NO. 93-SEQ ID NO. 102.

7. The pluripotent stem cell or derivative thereof according to claim 3, wherein: shRNA and/or miRNA processing complex related genes and/or anti-interferon effector molecules are also introduced into the genome of the pluripotent stem cell or the derivative thereof.

8. The pluripotent stem cell or derivative thereof according to claim 7, wherein: the shRNA and/or miRNA processing complex related gene comprises at least one of Drosha, Ago1, Ago2, Dicer1, Exportin-5, TRBP (TARBP2), PACT (PRKRA) and DGCR 8; the interferon effector molecule is at least one of shRNA and/or shRNA-miR resisting PKR, 2-5As, IRF-3 or IRF-7.

9. The pluripotent stem cell or derivative thereof according to claim 7, wherein: the target sequence of the shRNA and/or shRNA-miR resisting PKR, 2-5As, IRF-3 or IRF-7 is shown As SEQ ID NO. 103-SEQ ID NO. 162.

10. The pluripotent stem cell or the derivative thereof according to claim 6 or 9, wherein: the expression frameworks of the major histocompatibility complex gene, the major histocompatibility complex related gene, the shRNA and/or shRNA-miR resisting PKR, 2-5As, IRF-3 or IRF-7 are As follows:

(1) shRNA expression framework: the 5 'end to the 3' end sequentially comprises an shRNA target sequence, a stem-loop sequence, a reverse complementary sequence of the shRNA target sequence and Poly T; the shRNA target sequence is shown in claim 6 or 9;

(2) shRNA-miR expression framework: replacing the microRNA-30 target sequence with the shRNA-miR target sequence of claim 6 or 9.

11. The pluripotent stem cell or derivative thereof of claim 10, wherein: the length of the stem-loop sequence is 3-9 bases; the poly T is 5-6 bases in length.

12. The pluripotent stem cell or the derivative thereof according to claim 3 or 7, wherein: an inducible gene expression system is also introduced into the genome of the pluripotent stem cells or the derivatives thereof and is used for regulating and controlling the expression of immune compatible molecules and/or shRNA and/or miRNA processing complex related genes and/or anti-interferon effector molecules.

13. The pluripotent stem cell or derivative thereof of claim 12, wherein: the inducible gene expression system comprises a Tet-Off system or a dimer inducible expression system.

14. The pluripotent stem cell or derivative thereof of claim 12, wherein:

the introduction of the expression sequence of the IL-2, the expression sequence of the immune compatible molecule, the shRNA and/or miRNA processing complex related gene, the anti-interferon effector molecule and the inducible gene expression system adopts a method of viral vector interference, non-viral vector transfection or gene editing, and the method of gene editing comprises gene knock-in.

15. The pluripotent stem cell or derivative thereof of claim 12, wherein:

the introduction sites of the expression sequence of the IL-2, the expression sequence of the immune compatible molecule, the shRNA and/or miRNA processing complex related gene, the anti-interferon effector molecule and the inducible gene expression system are genome safety sites of the pluripotent stem cell or the derivative thereof.

16. The pluripotent stem cell or derivative thereof of claim 15, wherein: the genome safe site comprises one or more of an AAVS1 safe site, an eGSH safe site and an H11 safe site.

17. The pluripotent stem cell or the derivative thereof according to any one of claims 1 to 9, 11, 13 to 16, wherein:

the pluripotent stem cells comprise embryonic stem cells, embryonic germ cells, embryonic cancer cells, or induced pluripotent stem cells;

the pluripotent stem cell derivative includes an adult stem cell, each germ layer cell or tissue into which the pluripotent stem cell is differentiated;

the adult stem cells include mesenchymal stem cells or neural stem cells.

18. The pluripotent stem cell or derivative thereof according to claim 1, wherein: the nucleotide sequence of the IL-2 is shown in SEQ ID NO. 1.

19. Use of the pluripotent stem cell or derivative thereof according to any one of claims 1 to 18 for the manufacture of a medicament for the treatment of a tumor with high IL-2 expression.

20. A formulation comprising the pluripotent stem cells or derivatives thereof of any of claims 1 to 17, and a pharmaceutically acceptable carrier, diluent or excipient.

Images